-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Relapsed/refractory diffuse large B-lymphocyte tumors (RR DLBCL) have limited options after ≥2 lines of treatment progress, and the expected overall survival (OS) is <6 months
.
The SADAL study evaluated the efficacy of single-agent selinexor (selinexor) in the treatment of RR DLBCL.
Relapsed/refractory diffuse large B-lymphocyte tumors (RR DLBCL) have limited options after ≥2 lines of treatment progress, and the expected overall survival (OS) is <6 months
The median age was 67 years, and 44.
8% of patients were ≥70 years old
.
At a median follow-up of 14.
The median age was 67 years, and 44.
Subgroup survival comparison
Subgroup survival comparisonThe median OS of patients with or without autologous stem cell transplantation (ASCT) was 10.
9 months and 7.
8 months, respectively (HR 1.
39 (0.
85, 2.
28), p = 0.
185)
.
Among patients receiving current systemic treatment, the median OS of patients who reached CR or PR was significantly prolonged (11.
The median OS of patients with or without autologous stem cell transplantation (ASCT) was 10.
Impact of previous treatment on survival
Impact of previous treatment on survivalThe study observed that one patient with an expected survival of less than 6 months achieved a median survival of 9 months after using selinexor
.
It was also observed that 4 patients had not achieved CR in previous treatments, and achieved CR or PR after using selinexor
The study observed that one patient with an expected survival of less than 6 months achieved a median survival of 9 months after using selinexor
In summary, selinexor can obtain survival benefits in the treatment of relapsed/refractory diffuse large B lymphocyte tumors, regardless of age, previous ASCT treatment and refractory status
Original source:
Maerevoet M, Zijlstra JM, Follows G, et al.
Maerevoet M, Zijlstra JM, Follows G, et al.
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
J Hematol Oncol.
2021 Jul 16;14(1):111.
doi: 10.
1186/s13045-021-01122-1.
PMID: 34271963; PMCID: PMC8283921.
Leave a message here